Cube Labs Portfolio Holdings Valued at EUR 96.95 Million on Average

• Cube Labs published a EUR 96.95 million portfolio valuation dated December 31, 2025; Adamas Biotech reported positive IBS-C trial results.
• Bio Aurum extended its trial through fourth-quarter 2026; Biodiapers secured European and Indian patents; Cartilago advanced preclinical planning.
• Crati River Valley sought development funding; DTech completed nasal-spray safety testing; Hiperforming Research developed an AI prototype targeting India's hospital market.
• Lipovexa secured a US metabolic-treatment patent; Lumina Nanobiotech initiated patent drafting; Molecular Research evaluated a revised diabetic-neuropathy development strategy.
• Orpha Biotech secured patent protection for therapeutic compounds; Rescue Code obtained European patent acceptance; Skin Plastic Lab began device prototyping.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cube Labs S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20282-32-2026_TELEBORSA.pdf), on October 15, 2026, and is solely responsible for the information contained therein.